ReviewThe role of the actomyosin system in regulating trabecular fluid outflow
Introduction
The trabecular meshwork (TM) consists of arrays of collagen beams covered by endothelial-like cells, with loose extracellular matrix (ECM) occupying the spaces between the cells of the adjacent beams. The outermost juxtacanalicular (JXT) or cribriform region has no collagenous beams, but rather several cell layers immersed in a loose web of ECM fibrils. The adjacent Schlemm's canal is a continuous endothelium-lined channel that drains aqueous humor to the general venous circulation (Lütjen-Drecoll et al., 1981, Rohen et al., 1981). TM structure and experimental flow studies suggest that flow resistance is maximal in the JXT region and/or the inner wall of Schlemm's canal, although the exact location of the major resistance barrier is not clear (Johnson, 2006). Glaucoma is a progressive optic neuropathy commonly associated with elevated intraocular pressure (IOP) consequent to abnormally high resistance to aqueous humor drainage via the TM and Schlemm's canal. Glaucomatous eyes exhibit fewer TM cells and abnormally appearing JXT ECM compared to the eyes of age-matched normal individuals (Lütjen-Drecoll et al., 1981, Rohen et al., 1981), suggesting that cells and ECM in the JXT region may be critical in resistance regulation.
The actomyosin system, composed of actin microfilaments and associated proteins, is present in essentially all cells, and is highly organized in TM and Schlemm's canal cells. There are numerous microfilament-based structures in cells along the trabecular outflow pathway. These structures primarily include focal contacts, adherens cell–cell junctions, and bundles of microfilaments (Geiger et al., 1995). Filamentous actin is the major component of microfilaments, but other actin-associated proteins modulate its organization. Additionally, a physiologically contracted state of the JXT-Schlemm's canal region is required to maintain the microfilament-related structures in the outflow pathway. Microfilaments are involved in a variety of cellular processes from cell adhesion and motility to organelle traffic to adhesion-mediated signal transduction. Therefore, dynamics of the actomyosin system play important roles in changes in cell shape, volume, contractility, and adhesion to neighboring cells and to the ECM. These changes in TM and/or Schlemm's canal cells, which could affect trabecular outflow resistance by altering the dimensions or direction of flow pathways and the amount and composition of the ECM, can be modulated directly by actin-disrupting agents or indirectly by inhibition of specific protein kinase(s) or cellular contractility through administration of protein kinase inhibitors or gene therapy. In this review, we discuss the effects of pharmacological and genetic perturbation of the actomyosin system in TM and Schlemm's canal cells on trabecular outflow resistance.
Section snippets
Microfilament disruptors
Latrunculins, marine macrolides that are specific and potent actin-disrupting agents, sequester monomeric G-actin, leading to massive disassembly of filamentous actin. Addition of latrunculin A or B (LAT-A, LAT-B) causes destruction of actin bundles and associated proteins in a wide variety of cell types, including human TM cells (Cai et al., 2000, Epstein et al., 1999). This effect is manifested by cell rounding and retraction of the lamellipodium, and accompanied by an apparent “arborization”
Protein kinase inhibitors
The serine–threonine kinase inhibitor H-7, which affects a broad spectrum of protein kinases including myosin light chain kinase (MLCK), Rho kinase, and protein kinase C (PKC), inhibits actomyosin-driven contractility dramatically. This leads to cellular relaxation, deterioration of the actomyosin system and perturbation of its membrane anchorage, and loss of stress fibers and focal contacts in many types of cultured cells (Bershadsky et al., 1996, Epstein et al., 1999, Liu et al., 2001, Tian
Exoenzyme C3 transferase and nonmuscle caldesmon
TM relaxation can also be induced by modulating proteins, such as caldesmon, that negatively regulate actin–myosin interactions. When caldesmon is overexpressed, actin becomes uncoupled from myosin. Additionally, exoenzyme C3 transferase may also affect actin–myosin interactions by inhibiting Rho-GTP at the beginning of the Rho activation cascade, thereby blocking the whole Rho cascade. Within these pathways and among the end products are numerous targets not only for pharmacologic but also for
Microtubule inhibitors
The microtubule system is composed of microtubules and associated proteins, and is one of the three major systems (the microfilament system, the microtubule system and the intermediate filament system) in the cytoskeleton network. Apparently, dynamics of the microtubule system may modulate outflow resistance since microtubule inhibitors increase outflow facility. Microtubules are not intrinsically contractile, but are important for directional cell motility and, driven by specific microtubule
Clinical relevance
At present, the only effective approach available to treat glaucoma is to reduce IOP. Hypotension medications used clinically include aqueous humor secretory inhibitors (e.g., beta-adrenergic receptor antagonists, alfa2-adrenergic agonists, and carbonic anhydrase inhibitors), uveoscleral-outflow enhancers (e.g., prostaglandin analogues), cholinergic drugs that affect trabecular outflow indirectly by contracting the ciliary muscle and deforming the TM, and epinephrine drugs that work on both the
Conclusions
This review has provided evidence supporting the crucial role of the actomyosin system in TM cells and endothelium of Schlemm's canal in regulating trabecular fluid outflow. Relaxation of the TM and/or inner wall of Schlemm's canal, which may be induced by pharmacological or genetic perturbation of the actin cytoskeleton, is the major structural change responsible for the increase in trabecular outflow facility. Cytoskeletal drugs and/or cytoskeleton-modulating gene therapies may have potential
Acknowledgements
This study was supported by grants from the US National Eye Institute (EY002698 and EY016665), Research to Prevent Blindness, the Wisconsin Alumni Research Foundation, and the Ocular Physiology Research and Education Foundation. BG is the incumbent of the E. Neter Chair in Cell and Tumor Biology.
References (53)
- et al.
Involvement of microtubules in the control of adhesion-dependent signal transduction
Curr. Biol.
(1996) - et al.
Tensegrity and mechanoregulation: from skeleton to cytoskeleton
Osteoarthr. Cartil.
(1999) - et al.
Caldesmon transgene expression disrupts focal adhesions in HTM cells and increases outflow facility in organ-cultured human and monkey anterior segments
Exp. Eye Res.
(2006) - et al.
Caldesmon effects on the actin cytoskeleton and cell adhesion in cultured HTM cells
Exp. Eye Res.
(2006) - et al.
Monkey organ-cultured anterior segments: technique and response to H-7
Exp. Eye Res.
(2006) What controls aqueous humour outflow resistance?
Exp. Eye Res.
(2006)- et al.
The role of protein kinase C in modulation of aqueous humor outflow facility
Exp. Eye Res.
(2003) - et al.
The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes
Exp. Eye Res.
(2008) - et al.
The effect of intracamerally injected ethacrynic acid on intraocular pressure in patients with glaucoma
Am. J. Ophthalmol.
(1992) - et al.
A mechanism for trabecular meshwork cell retraction: ethacrynic acid initiates the dephosphorylation of focal adhesion proteins
Exp. Eye Res.
(1997)
Effect of latrunculin-B on outflow facility in monkeys
Exp. Eye Res.
Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility
Exp. Eye Res.
Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork
Exp. Eye Res.
Functional and structural reversibility of H-7 effects on the conventional aqueous outflow pathway in monkeys
Exp. Eye Res.
Latrunculin B effects on trabecular meshwork and corneal endothelial morphology in monkeys
Exp. Eye Res.
ML-7, chelerythrine and phorbol ester increase outflow facility in the monkey eye
Exp. Eye Res.
Effects of the rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys
Exp. Eye Res.
The regulation of trabecular meshwork and ciliary muscle contractility
Prog. Retin. Eye Res.
Pharmacologic disruption of Schlemm's canal cells and outflow facility in anterior segments of human eyes
Invest. Ophthalmol. Vis. Sci.
Effect of latrunculin-A on morphology and actin-associated adhesions of cultured human trabecular meshwork cells
Mol. Vis.
Influence of ethacrynic acid on outflow facility in the monkey and calf eye
Invest. Ophthalmol. Vis. Sci.
Acto-myosin drug effects and aqueous outflow function
Invest. Ophthalmol. Vis. Sci.
Ethacrynic acid induces reversible shape and cytoskeletal changes in cultured cells
Invest. Ophthalmol. Vis. Sci.
Effects of latrunculin-B on outflow facility and trabecular meshwork structure in human eyes
Invest. Ophthalmol. Vis. Sci.
Molecular interactions in the submembrane plaque of cell–cell and cell–matrix adhesions
Acta Anat. (Basel)
Effects of protein kinase inhibitor, HA1077, on intraocular pressure and outflow facility in rabbit eyes
Arch. Ophthalmol.
Cited by (106)
The vital role for nitric oxide in intraocular pressure homeostasis
2021, Progress in Retinal and Eye ResearchThe trabecular meshwork: Structure, function and clinical implications. A review of the littérature (French translation of the article)
2020, Journal Francais d'OphtalmologieThe trabecular meshwork: Structure, function and clinical implications. A review of the literature
2020, Journal Francais d'OphtalmologieConnective tissue growth factor: Role in trabecular meshwork remodeling and intraocular pressure lowering
2023, Experimental Biology and MedicineResearch progress of SIP signaling pathway in eye diseases
2023, Chinese Journal of Experimental OphthalmologyCCN2/CTGF tip the balance of growth factors towards TGF-β2 in primary open-angle glaucoma
2023, Frontiers in Molecular Biosciences